Canada: Appeal Relating To Olanzapine Patent Dismissed (Intellectual Property Weekly Abstracts Bulletin: Week Of September 24, 2012)

Last Updated: September 27 2012
Most Read Contributor in Canada, September 2016

Edited by Chantal Saunders and Beverley Moore


Appeal Relating to Olanzapine Patent Dismissed

Eli Lilly Canada Inc. v. Novopharm Limited


The Court heard this patent infringement action relating to olanzapine in 2009 and found that the patent was invalid. The Court of Appeal held that the Court erred in finding that the conditions for a valid selection patent can be an independent allegation of invalidity. The Court of Appeal found that the patent at issue was not invalid for anticipation, double patenting or obviousness, and referred the issues of utility and sufficiency back to the Court. Upon reconsideration, the Federal Court held that there was no demonstration of utility and no sound prediction for the promise found by the Court. The patent contained the results of human clinical trials on patients suffering from schizophrenia, and information relating to olanzapine's side effect profile.

The Court of Appeal dismissed the appeal, finding no error of law or principle or any palpable and overriding error of fact.

Other Cases of Interest

Injunction Issued to Prevent Use of Copies of Tests to Prepare Students

Canada (Attorney General) v. Rundle (Nec Plus Ultra)

This is an application in the Ontario Superior Court of Justice for an injunction, in which the Attorney General is seeking to prevent Rundle from continuing to use copies of the Public Service Commission's (PSC) Second Language (French) Evaluation Test (SLE) in her courses to prepare students for the SLE Test. The SLE Tests were developed using taxpayer money to assess applicants for bilingual positions with the Federal Government and are stamped "Subject to Copyright Protection".

The Attorney General established that there is a serious issue to be tried. With respect to irreparable harm, the Court found that the individuals taking Rundle's course that have access to materials that are substantially the same as the official SLE Test have an unfair advantage compared to other test takers. The Court found that access to test questions causes the PSC irreparable harm in that the PSC cannot ensure compliance with the Official Languages Act. Rundle argued that her business would suffer irreparable harm if she was not allowed to continue to use a copy of the test to prepare her students. The Court found that this was not the case because she never had permission to use a copy of the SLE Tests in the first place. Finally, the Court found that the balance of convenience favours allowing Rundle to continue to operate her teaching business but without use of the official SLE Test questions.

Accordingly, Rundle was enjoined from copying, reproducing, distributing, making available to the public or any clients questions that are substantially similar to the SLE Tests.

No Reviewable Error in Rejection of SNDS

Duchesnay Inc. v. Canada (Attorney General)


This is an application for judicial review of a decision issuing a Notice of Deficiency-Withdrawal (NOD-W) in response to a Supplemental New Drug Submission (SNDS). The decision under review related to the inclusion of two clinical studies. Health Canada refused to include the studies in the Product Monograph.

The Court considered a preliminary issue of whether additional evidence could be filed before the Court. The Court refused to allow the additional evidence, which consisted of an affidavit attaching a transcript of an examination for discovery on the basis that discovery is confidential.

The Court held that there was no reviewable error by the Minister of Health in rejecting the SNDS. Further, the Court held that the Minister of Health did not commit a breach of procedural fairness.

Court Holds Reasonable Finding Relating to Safety and Efficacy of Ingredient

North American Nutriceutical Inc v. Canada (Attorney General)

Drug: TherapeutxTM "Maori Miracle" Joint Health Companion

This is an application pursuant to Section 18.1(1) of the Federal Courts Act, in which the Applicant is seeking judicial review of a decision made by the Natural Health Products Directorate (NHPD) refusing a product licence application.

The Court first noted that the decision by the NHPD is reviewable on a reasonableness standard but a standard of correctness for issues of procedural fairness applies. The Court found that the NHPD came to a reasonable finding that the evidence relating to the safety and efficacy of one of the ingredients of the product was deficient and there was no breach of procedural fairness. The Court found that the NHPD continually noted its concern with respect to the lack of information about the safety of the ingredient in the Applicant's product.

Dismissal of Copyright Infringement Action for Computer Programs Dismissed

Harmony Consulting Ltd. v. G.A. Foss Transport Ltd.

This is an appeal from a decision of the Federal Court, in which the Court dismissed an action for copyright infringement. The Court of Appeal considered grounds of appeal relating to originality, ownership and infringement, and dismissed the appeal.

Patent Appeal Board Finds Sound Prediction and Definite Claims

Commissioner's Decision No. 1329

This decision relates to a patent application entitled "Viruses for the Treatment of Cellular Proliferative Disorders". The Examiner rejected the application on the basis of anticipation, obviousness, lack of support, and/or indefiniteness. The Patent Appeal Board (PAB) found certain claims to be anticipated by the cited prior art. The PAB also found a number of claims obvious.

The Examiner found that the claimed use is not soundly predicted because there was no demonstration of the use of any of the specific viruses recited in the proposed claims and because there was no factual basis nor an enabling specification as undue experimentation would have been required to practice the invention. The PAB found that the claims are based on a properly supported sound prediction and the disclosure was adequately enabled. Finally, the PAB found that the person of skill in the art "would have no difficulty understanding and predicting what modified viruses fall with the scope of the proposed claims and thus, the proposed claims are definite and comply with subsection 27(4) of the Patent Act."

The Commissioner of Patents concurred with the recommendations of the PAB that certain amendments be made to the remaining claims and the application issued.

Other Industry News

CIPO has posted an Update re, indicating that it is still reviewing the feedback from the consultation period for its Practice Notice and will provide a further update at the beginning of October 2012.

The Competition Bureau announced that it has released its final Enforcement Guidelines on the Abuse of Dominance Provisions (Sections 78 and 79 of the Competition Act). The updated guidelines are now available on the Bureau's website.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.